{"schema_version":"secwatch.filing_event.v1","accession":"0001662774-25-000011","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.358783+00:00","generated_at":"2026-05-24T06:41:42.611254+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Quince Therapeutics FY2024 net loss $56.8M; Phase 3 NEAT trial exceeds 50% enrollment","bullets":["Net loss of $56.8M ($1.31/share) for FY2024; cash $40.8M provides runway into 2026.","Phase 3 NEAT trial enrolled 61 participants (>50%); topline results expected Q4 2025.","Received FDA Fast Track designation (June 2024); Phase 3 ATTeST results published in The Lancet Neurology.","R&D $18.6M, G&A $17.6M; operating cash burn $31.9M includes $5M milestone and $17.1M goodwill impairment.","Appointed Dr. William Whitehouse to SAB; USPTO allowed patent claims extending to 2036 for eDSP in A-T."],"urls":{"canonical":"https://secwatch.observer/filing/0001662774-25-000011","json":"https://secwatch.observer/filing/0001662774-25-000011.json","markdown":"https://secwatch.observer/filing/0001662774-25-000011.md","text":"https://secwatch.observer/filing/0001662774-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000166277425000011/0001662774-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000166277425000011/qncx-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:41:42.611254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}